<?xml version='1.0' encoding='utf-8'?>
<document id="30893910"><sentence text="Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban."><entity charOffset="11-20" id="DDI-PubMed.30893910.s1.e0" text="Verapamil" /><entity charOffset="25-34" id="DDI-PubMed.30893910.s1.e1" text="Diltiazem" /><entity charOffset="83-94" id="DDI-PubMed.30893910.s1.e2" text="Rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.30893910.s1.e0" e2="DDI-PubMed.30893910.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30893910.s1.e0" e2="DDI-PubMed.30893910.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30893910.s1.e0" e2="DDI-PubMed.30893910.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30893910.s1.e1" e2="DDI-PubMed.30893910.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30893910.s1.e1" e2="DDI-PubMed.30893910.s1.e2" /></sentence><sentence text="Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs"><entity charOffset="19-30" id="DDI-PubMed.30893910.s2.e0" text="rivaroxaban" /><entity charOffset="40-63" id="DDI-PubMed.30893910.s2.e1" text="dihydropyridine calcium" /><entity charOffset="130-141" id="DDI-PubMed.30893910.s2.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.30893910.s2.e0" e2="DDI-PubMed.30893910.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30893910.s2.e0" e2="DDI-PubMed.30893910.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30893910.s2.e0" e2="DDI-PubMed.30893910.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30893910.s2.e1" e2="DDI-PubMed.30893910.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30893910.s2.e1" e2="DDI-PubMed.30893910.s2.e2" /></sentence><sentence text=" This study was designed to evaluate the effects of verapamil and diltiazem on the pharmacokinetics and the prolongation of prothrombin time of rivaroxaban in rats"><entity charOffset="52-61" id="DDI-PubMed.30893910.s3.e0" text="verapamil" /><entity charOffset="66-75" id="DDI-PubMed.30893910.s3.e1" text="diltiazem" /><entity charOffset="144-155" id="DDI-PubMed.30893910.s3.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.30893910.s3.e0" e2="DDI-PubMed.30893910.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30893910.s3.e0" e2="DDI-PubMed.30893910.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30893910.s3.e0" e2="DDI-PubMed.30893910.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30893910.s3.e1" e2="DDI-PubMed.30893910.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30893910.s3.e1" e2="DDI-PubMed.30893910.s3.e2" /></sentence><sentence text=" The data were analyzed using a pharmacokinetic/pharmacodynamics (PK/PD) modeling approach to quantify the influence of verapamil"><entity charOffset="120-129" id="DDI-PubMed.30893910.s4.e0" text="verapamil" /></sentence><sentence text=" Verapamil increased the systemic exposure of rivaroxaban by 2"><entity charOffset="46-57" id="DDI-PubMed.30893910.s5.e0" text="rivaroxaban" /></sentence><sentence text="8-fold (p &lt;0" /><sentence text="001) which was probably due to the inhibition of efflux transportation rather than metabolism" /><sentence text=" Prothrombin time was also prolonged in a proportional manner; diltiazem did not show any significant effects, however" /><sentence text=" A transit PK model in the absorption process comprehensively describes the double-peaks of rivaroxaban plasma concentrations and the corresponding change of prothrombin time with a simple linear relationship"><entity charOffset="92-103" id="DDI-PubMed.30893910.s9.e0" text="rivaroxaban" /></sentence><sentence text=" The slope of prothrombin time vs" /><sentence text=" rivaroxaban plasma concentration in rats was retrospectively found to be insensitive by about 5"><entity charOffset="1-12" id="DDI-PubMed.30893910.s11.e0" text="rivaroxaban" /></sentence><sentence text="4-fold compared to than in humans" /><sentence text=" More than a 67% dose reduction in rivaroxaban is suggested in terms of both a pharmacokinetic point of view, and the sensitivity differences on the prolongation of prothrombin time when used concomitantly with verapamil"><entity charOffset="35-46" id="DDI-PubMed.30893910.s13.e0" text="rivaroxaban" /><entity charOffset="211-220" id="DDI-PubMed.30893910.s13.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.30893910.s13.e0" e2="DDI-PubMed.30893910.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30893910.s13.e0" e2="DDI-PubMed.30893910.s13.e1" /></sentence><sentence text="" /></document>